QUOTE AND NEWS
PR Newswire  May 23  Comment 
PHILADELPHIA, May 23, 2012 /PRNewswire/ -- Today, the American College of Endocrinology (ACE) and Lilly Diabetes launched the "EmPower Diabetes Emergency Plan" - a newly designed resource to help people with diabetes prepare for emergency situations
FierceBiotech  May 22  Comment 
The FDA's demanding requirements on cardio safety data has made diabetes one of the most challenging diseases in the drug development world. Today, Eli Lilly ($LLY) demonstrated that its late-stage diabetes drug dulaglutide cleared an important...
PR Newswire  May 22  Comment 
NEW YORK, May 22, 2012 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY) today announced that dulaglutide, its investigational, long-acting glucagon-like peptide 1 (GLP-1) analog being studied as a once-weekly treatment for type 2 diabetes, met its
MedPage Today  May 16  Comment 
CHICAGO (MedPage Today) -- A well-known anti-psychotic drug can help cancer patients bear some of the side effects of chemotherapy, a researcher said.
Market Intelligence Center  May 16  Comment 
Eli Lilly (NYSE:LLY) closed Tuesday's wandering trading session at $40.58. In the past year, the stock has hit a 52-week low of $33.75 and 52-week high of $42.03. Eli Lilly (LLY) stock has been showing support around $40.18 and resistance in the...
PR Newswire  May 14  Comment 
INDIANAPOLIS, May 14, 2012 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY) will present data from more than 25 studies at the 48th Annual Meeting of the American Society of Clinical Oncology (ASCO) in Chicago, Ill. from June 1 - 5, 2012, including
PR Newswire  May 14  Comment 
INDIANAPOLIS, May 14, 2012 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY) will present data from several molecules that make up its clinical oncology pipeline during the 48th Annual Meeting of the American Society of Clinical Oncology (ASCO) held
FiercePharma  May 10  Comment 
Don't count pharma out in the sales-rep overtime fight. As Pharmalot reports, a U.S. appeals court has denied overtime for Eli Lilly ($LLY) and Abbott Laboratories ($ABT) sales reps. The reps qualify for the Fair Labor Standards Act's...
Market Intelligence Center  May 10  Comment 
Eli Lilly (NYSE:LLY) closed Wednesday's downbeat trading session at $41.30. In the past year, the stock has hit a 52-week low of $33.75 and 52-week high of $42.03. Eli Lilly (LLY) stock has been showing support around $40.79 and resistance in the...
FierceBiotech  May 7  Comment 
A secretive startup at Lilly Ventures in Indianapolis has grabbed $4.6 million of a documented $15 million round of equity financing, MedCity News reported, citing SEC documents. The recently founded Esanex doesn't appear to have a website or a...




 

Very nice site!

Wikinvest © 2006, 2007, 2008, 2009, 2010, 2011, 2012. Use of this site is subject to express Terms of Service, Privacy Policy, and Disclaimer. By continuing past this page, you agree to abide by these terms. Any information provided by Wikinvest, including but not limited to company data, competitors, business analysis, market share, sales revenues and other operating metrics, earnings call analysis, conference call transcripts, industry information, or price targets should not be construed as research, trading tips or recommendations, or investment advice and is provided with no warrants as to its accuracy. Stock market data, including US and International equity symbols, stock quotes, share prices, earnings ratios, and other fundamental data is provided by data partners. Stock market quotes delayed at least 15 minutes for NASDAQ, 20 mins for NYSE and AMEX. Market data by Xignite. See data providers for more details. Company names, products, services and branding cited herein may be trademarks or registered trademarks of their respective owners. The use of trademarks or service marks of another is not a representation that the other is affiliated with, sponsors, is sponsored by, endorses, or is endorsed by Wikinvest.
Powered by MediaWiki